Phase 1 Newly Diagnosed Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled5 locationsNCT06622434
Recruiting
Phase 1
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting
Phase 1Phase 2
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Newly Diagnosed MGMT Unmethylated Glioblastoma
Darell Bigner50 enrolled1 locationNCT05734560
Recruiting
Phase 1Phase 2
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
LeukemiaNewly DiagnosedMyeloid+1 more
Molecular Partners AG249 enrolled9 locationsNCT05673057
Recruiting
Phase 1Phase 2
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Newly Diagnosed Diffuse Large B-cell Lymphoma
Mingzhi Zhang80 enrolled1 locationNCT06683885
Recruiting
Phase 1Phase 2
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Newly Diagnosed Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.58 enrolled1 locationNCT05445154
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001501134
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001492145
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001352190
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione capsule against the innovator 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione capsule conducted under fasting conditions in healthy male volunteers.
4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12619001338156
Completed
Phase 1
High-dose lenalidomide maintenance therapy in adult acute myeloid leukaemia (AML)
Newly diagnosed acute myeloid leukaemia (except Acute promyelocytic leukaemia (APML))
Australasian Leukaemia and Lymphoma Group (ALLG)50 enrolled1 locationACTRN12610000627055